Mink therapeutics reports corporate update and first quarter 2023 financial results

New york, may 11, 2023 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today provided a corporate update and reported financial results for the first quarter 2023.
INKT Ratings Summary
INKT Quant Ranking